LYONS GARY A
SEC Form 4 insider trading activity
LYONS GARY A has filed 5 SEC Form 4 filings (13 transaction rows) across 2 companies, including TVTX, NBIX, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, LYONS GARY A is listed as Director at Travere Therapeutics, Inc. Inside the rolling window, LYONS GARY A reported no open-market purchases and 4 open-market sales totaling $3.3M in TVTX and NBIX. The largest disclosed transaction in the window is a sale of 15,000 NBIX shares on Dec 3, 2025, worth $2.3M.
Companies traded
Other insiders at TVTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.3M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has LYONS GARY A made?
LYONS GARY A has filed 5 SEC Form 4 filings (13 transaction rows) across 2 companies, including TVTX, NBIX since 2025.
Which companies does LYONS GARY A trade?
LYONS GARY A has filed SEC Form 4 disclosures for 2 companies, including TVTX, NBIX.
When was LYONS GARY A's most recent SEC Form 4 filing?
LYONS GARY A's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is LYONS GARY A's total buy and sell value in the current window?
Inside the rolling retention window, LYONS GARY A bought $0 and sold $3.3M based on SEC Form 4 filings.
What was LYONS GARY A's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 15,000 NBIX shares on 2025-12-03, worth $2.3M, per SEC Form 4 filings.